News | Endoscopes | April 02, 2018

WATS3D Endoscopy Device Improves Esophageal Cancer Detection by 80 Percent

Multicenter prospective study results show with inclusion of WATS3D, overall detection of Barrett’s esophagus increased 83 percent, detection of dysplasia increased 88 percent

April 2, 2018 — Results from a recent prospective trial found the Wide Area Transepithelial Sampling with 3D Tissue Analysis (WATS3D) device increases the detection of both Barrett’s esophagus and esophageal dysplasia by more than 80 percent. Study results from the multicenter trial of more than 4,000 patients were published in the latest issue of United European Gastroenterology Journal and featured in the American Society for Gastrointestinal Endoscopy (ASGE)’s Scope Tech Talk video series.

Esophageal adenocarcinoma, one of the most fatal and fastest growing cancers in the U.S., can be prevented if detected at a precancerous stage. Gastroenterologists perform more than 5 million upper endoscopies each year on patients with chronic heartburn and Barrett's esophagus in an effort to find these precancerous cells before they can progress to cancer. A major problem with this strategy is that prior to the availability of WATS3D, endoscopists had to rely on taking small random forceps biopsies at 1-2 cm intervals to find these abnormal cells, leaving more than 96 percent of the endoscopically suspect area completely untested.

With the availability of WATS3D, doctors are able to rapidly collect a sample from a much larger surface area of the esophagus. By combining a larger sampling area with 3-D imaging and cytopathology, WATS3D has far reaching implications for protecting a patient’s health, according to CDx Diagnostics, the makers of the solution. If precancerous cells are present, they can now be easily detected and removed or destroyed before they become cancerous – essentially pre-empting esophageal cancer.

The multicenter prospective trial was conducted at 25 community-based gastrointestinal (GI) centers across the United States. In the study, 4,203 patients were tested for esophageal disease. The findings show that with the inclusion of WATS3D overall detection of Barrett’s increased by 83 percent, while the detection of dysplasia increased by 88 percent. The study concludes that the sampling error can be improved dramatically with use of this adjunctive technique.

“These data confirm findings from previous clinical trials showing that WATS3D biopsy significantly increases the detection rate of Barrett's Esophagus as well as precancerous changes in esophageal tissue in GERD patients," said Seth Gross, M.D., lead investigator. “Ultimately, WATS3D revolutionary technology is making esophageal cancer a potentially preventable disease.”

“This study exhibits the fundamental limitation with standard forceps biopsies in the setting of Barrett’s diagnosis and surveillance and sheds light on the 'sampling error' phenomenon that may provide false reassurance to both patients and GI professionals,” said Vivek Kaul, M.D., Segal-Watson Professor of Medicine and chief of the Division of Gastroenterology and Hepatology at the University of Rochester Medical Center. “These results clearly demonstrate that the wide-area sampling and expert analysis aspects of WATS3D technology can effectively help fill the information gap in diagnosis and surveillance for patients with Barrett’s esophagus.”

For more information: www.wats3d.com

 

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
New Lung Ambition Alliance Aims to Double Five-year Lung Cancer Survival by 2025
News | Lung Cancer | July 17, 2019
The International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...
Therapixel Appoints Matthieu Leclerc-Chalvet as CEO
News | Artificial Intelligence | July 03, 2019
Artificial intelligence (AI) breast cancer screening specialist Therapixel announced the appointment of Matthieu...
Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...